Physician profile
Kaywin M Carter
NPI 1295802668
$982.02
in general payments reported to CMS, 2019-2025
17 companies · $14.50 in 2025
The $14.50 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.17 · 2020: $183 · 2021: $115 · 2022: $299 · 2023: $241 · 2024: $48.81 · 2025: $14.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $304.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $315.18 | 2019-2023 | Lo Loestrin Fe, Orilissa, Liletta |
| Myovant Sciences INC. | $119.45 | 2021-2022 | |
| Astellas Pharma US INC | $85.15 | 2023-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $76.56 | 2023 | Myfembree |
| Kite Pharma, INC. | $76.49 | 2020 | |
| Gilead Sciences, INC. | $69.17 | 2022 | |
| Therapeuticsmd, INC. | $44.15 | 2020-2022 | |
| Ethicon US, LLC | $34.50 | 2024 | Dermabond Prineo |
| Baxter Healthcare | $27.71 | 2022 | |
| Merck Sharp & Dohme LLC | $24.61 | 2019 | |
| Exeltis, USA INC. | $21.54 | 2022 | |
| Smith+Nephew, INC. | $16.83 | 2019 | |
| Minerva Surgical, INC | $15.82 | 2022 | |
| Shire North American Group INC | $14.70 | 2019 | |
| Shield Therapeutics INC | $14.31 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $14.07 | 2020 | |
| Allergan, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaywin Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.